Jiangsu Key Laboratory for TCM Formulae Research, Pharmacy College, Nanjing University of Chinese Medicine, No 138 Xianlin Road, Nanjing 210046, China.
Toxicol In Vitro. 2013 Feb;27(1):396-401. doi: 10.1016/j.tiv.2012.08.011. Epub 2012 Aug 16.
Drug toxicity may occur due to dangerous drug combination. We aimed to investigate the influence of verapamil (a P-gp inhibitor)--bufadienolides interaction on cardiotoxicity and bufadienolide uptake by the isolated heart. The study was performed in Langendorff isolated perfused guinea-pig hearts by bufadienolides infusion in the absence and presence of verapamil (250, 500ng/ml). Arrhythmia parameters were evaluated by ECG and the content of bufadienolides in heart were measured by ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS). In the present of verapamil, the wide QRS duration and lightly rapid heart rate (HR) were markedly reduced in the early stage of bufadienolide intoxication. However, the ECG changes characterized by prolonged P-R interval, and slow heart rate and low QRS amplitude in the late stage of bufadienolide intoxication were significantly enhanced. Furthermore, the contents of a variety of bufadienolide compounds in the verapamil+bufadienolide group were significantly higher when cardiac arrest occurred. Although verapamil reduced the bufadienolide-induced ventricular arrhythmias, verapamil worsened heart block and lethal bradycardia of bufadienolides partly via increasing the uptake of bufadienolides in heart tissue, which could compromise the protective effects of verapamil against bufadienolide intoxication. These results suggested that the verapamil may produce dangerous interactions with drugs containing bufadienolides.
药物毒性可能由于危险的药物联合使用而发生。我们旨在研究维拉帕米(一种 P-糖蛋白抑制剂)-蟾毒配基相互作用对心脏毒性和蟾毒配基摄取的影响。这项研究是在 Langendorff 分离的豚鼠心脏中进行的,通过在没有和存在维拉帕米(250、500ng/ml)的情况下输注蟾毒配基。通过心电图评估心律失常参数,并通过超高效液相色谱串联质谱(UPLC-MS)测量心脏中蟾毒配基的含量。在维拉帕米存在的情况下,蟾毒配基中毒早期宽 QRS 持续时间和轻度快速心率(HR)明显减少。然而,在蟾毒配基中毒后期,心电图变化表现为延长 P-R 间隔、心率缓慢和 QRS 幅度低,明显增强。此外,当发生心脏骤停时,维拉帕米+蟾毒配基组中各种蟾毒配基化合物的含量明显升高。尽管维拉帕米降低了蟾毒配基引起的室性心律失常,但维拉帕米通过增加心脏组织中蟾毒配基的摄取,部分加重了心脏阻滞和蟾毒配基引起的致命性心动过缓,从而损害了维拉帕米对蟾毒配基中毒的保护作用。这些结果表明,维拉帕米可能与含有蟾毒配基的药物产生危险的相互作用。